Turbovas-ASP 15 Capsules

babies: it does not apply to babies. lactating mothers: it is unsafe to use this medicine during lactation.
human studies suggest that the drug passes into breast milk and harms the baby. pregnancy: it is unsafe to use this medicine during pregnancy.
human studies suggest that the drug causes harmful effects on the developing baby. alcohol: it is unsafe to consume alcohol while taking this medicine.
driving: this medicine causes dizziness, sleepiness, affects your vision and may decrease alertness. do not drive if these symptoms occur. liver: it is used with caution in patients with liver disease.
dose adjustment is needed. please consult your doctor before using this medicine.
it is not recommended in patients with severe liver disease. kidney: it is used with caution in patients with kidney disease.
dose adjustment is needed. please consult your doctor before using this medicine.
it is not recommended in patients with severe kidney disease. .

Increased bleeding tendency Dizziness Indigestion Muscle weakness Headache Constipation.

TURBOVAS-ASP capsule is a combination medicine used in the treatment of heart attack and stroke. rosuvastatin is a lipid-lowering agent that reduces bad cholesterol, triglycerides and increases good cholesterol.
aspirin is a nonsteroidal anti-inflammatory agent that consists of antiplatelet action and decreases the formation of harmful blood clots..

If you miss a dose of TURBOVAS-ASP, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• take TURBOVAS-ASP with food to avoid stomach upset • take this medicine as long as prescribed by your doctor and complete the entire course of this medicine • if you notice the yellowing of the skin, muscle pain, and dark urine while taking this medicine, inform your doctor immediately • avoid consumption of alcohol while taking this medicine.

• aspirin + alteplase: concurrent use leads to an increase in the risk of bleeding • aspirin + bromfenac: concurrent use leads to an increase in the risk of gastrointestinal ulcers and bleeding • rosuvastatin + calcium carbonate: concurrent use leads to a decrease in the therapeutic effect of rosuvastatin • rosuvastatin + dicumarol: concurrent use leads to an increase in the risk of bleeding • rosuvastatin + ethambutol: concurrent use leads to an increase in the risk of nerve damage.